scispace - formally typeset
R

Rabbab Oun

Researcher at Strathclyde Institute of Pharmacy and Biomedical Sciences

Publications -  9
Citations -  2883

Rabbab Oun is an academic researcher from Strathclyde Institute of Pharmacy and Biomedical Sciences. The author has contributed to research in topics: Cisplatin & Drug delivery. The author has an hindex of 8, co-authored 9 publications receiving 2211 citations. Previous affiliations of Rabbab Oun include University of Strathclyde & University of Glasgow.

Papers
More filters
Journal ArticleDOI

The status of platinum anticancer drugs in the clinic and in clinical trials.

TL;DR: The status of platinum anticancer drugs currently approved for use, those undergoing clinical trials and those discontinued during clinical trials are updated, and the results in the context of where the field will develop over the next decade are discussed.
Journal ArticleDOI

The side effects of platinum-based chemotherapy drugs: a review for chemists

TL;DR: Patients are commonly co-prescribed additional non-chemotherapy based drugs to treat the side effects which can include antiemetics, antibiotics and myeloid growth factors, mannitol, propafenone, saline hyperhydration, magnesium supplements, monoclonal antibody cytokine blockers, and antioxidants.
Journal ArticleDOI

The potential of cucurbit[n]urils in drug delivery

TL;DR: The potential use of cucurbiturils in drug delivery in the context of getting a new drug into clinical trials is examined and what further research is needed in this area is discussed.
Journal ArticleDOI

The ex vivo neurotoxic, myotoxic and cardiotoxic activity of cucurbituril-based macrocyclic drug delivery vehicles

TL;DR: The results show continued potential of cucurbiturils as drug delivery vehicles for the reduction of the side effects associated with platinum-based chemotherapy, and a relative lack of toxicity displayed by these macrocycles in whole animal acute systemic toxicity studies.
Journal ArticleDOI

Cucurbit[7]uril encapsulated cisplatin overcomes cisplatin resistance via a pharmacokinetic effect

TL;DR: The results provide the first example of overcoming drug resistance via a purely pharmacokinetic effect rather than drug design or better tumour targeting, and demonstrate that in vitro assays are no longer as important in screening advanced systems of drug delivery.